Is the IL-10 -819 polymorphism associated with visceral leishmaniasis?

Inflammation

Volumn 36, Issue 6, 2013, Pages 1513-1518

  Hajilooi, Mehrdad ^a   Sardarian, Kosro ^a   Dadmanesh, Maryam ^b   Matini, Mohamad ^a   Lotfi, Pegah ^a   Bazmani, Ahad ^c   Tabatabaiefar, Mohammad Amin ^d   Arababadi, Mohammad Kazemi ^e   Momeni, Mohammad ^e  

^a HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b AJA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e RAFSANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

IL 10; polymorphism; visceral leishmaniasis

Indexed keywords

BACTERIUM ANTIBODY; INTERLEUKIN 10;

ADULT; ALLELE; ANTIBODY TITER; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ETHNIC GROUP; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; IMMUNOFLUORESCENCE TEST; INTERLEUKIN 10 GENE; IRANIAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; VISCERAL LEISHMANIASIS;

ADULT; ANTIBODIES, PROTOZOAN; CROSS-SECTIONAL STUDIES; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTERLEUKIN-10; IRAN; LEISHMANIA; LEISHMANIASIS, VISCERAL; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RISK FACTORS; YOUNG ADULT;

EID: 84888197258     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-013-9693-0     Document Type: Article

References (31)

1. Hartemink, N., S.O. Vanwambeke, H. Heesterbeek, et al. 2011. Integrated mapping of establishment risk for emerging vector-borne infections: a case study of canine leishmaniasis in southwest France. PLoS One 6: e20817.
2. Newlove, T., M. Robinson, S.A. Meehan, et al. 2012. Old World cutaneous leishmaniasis. Dermatology Online Journal 18: 32.
3. Wilson, M.E., S.M. Jeronimo, and R.D. Pearson. 2005. Immunopathogenesis of infection with the visceralizing Leishmania species. Microbial Pathogenesis 38: 147-160.
4. Ali, N., A.H. Mekuria, J.M. Requena, et al. 2012. Immunity to visceral leishmaniasis. Journal Of Tropical Medicine 2012: 780809.
5. Groux, H., and F. Cottrez. 2003. The complex role of interleukin-10 in autoimmunity. Journal of Autoimmunity 20: 281-285.
6. Arababadi, M.K., A.A. Pourfathollah, A.A. Jafarzadeh, et al. 2010. Serum levels of Interleukin (IL)-10 and IL-17A in occult HBV infected south-east Iranian patients. Hepatitis Monthly 10: 31-35.
7. Arababadi, M.K., M. Mirzaei, S.M.A. Sajadi, et al. 2012. Interleukin (IL)-10 gene polymorphisms is associated with type 2 diabetes with and without nephropathy: a study of patients from the south-east region of Iran. Inflammation. doi: 10.1007/s10753-011-9381-x.
8. Gomes, N.A., C.R. Gattass, V. Barreto-De-Souza, et al. 2000. TGF-beta mediates CTLA-4 suppression of cellular immunity in murine kalaazar. Journal of Immunology 164: 2001-2008.
9. Bhattacharya P, Ali N (2013) Involvement and interactions of different immune cells and their cytokines in human visceral leishmaniasis. Revista da Sociedade Brasileira de Medicina Tropical. 46(2)
10. Lopez, P., C. Gutierrez, and A. Suarez. 2010. IL-10 and TNFalpha genotypes in SLE. Journal of Biomedicine and Biotechnology 2010: 838390.
11. Oshaghi, M.A., N.M. Ravasan, E.A. Javadian, et al. 2009. Vector incrimination of sand flies in the most important visceral leishmaniasis focus in Iran. The American Journal of Tropical Medicine and Hygiene 81: 572-577.
12. Oshaghi, M.A., N.M. Ravasan, M. Hide, et al. 2009. Phlebotomus perfiliewi transcaucasicus is circulating both Leishmania donovani and L. infantum in northwest Iran. Experimental Parasitology 123: 218-225.
13. Mohebali, M., E. Javadian, M.R. Yaghoobi-Ershadi, et al. 2004. Characterization of Leishmania infection in rodents from endemic areas of the Islamic Republic of Iran. Eastern Mediterranean Health Journal 10: 591-599.
14. Akaike, H. 1974. A new look at the statistical model identification. Automatic Control, IEEE Transactions on. 19: 716-723.
15. Ganguly, S., N.K. Das, M. Panja, et al. 2008. Increased levels of interleukin-10 and IgG3 are hallmarks of Indian post-kala-azar dermal leishmaniasis. Journal of Infectious Diseases 197: 1762-1771.
16. Saha, S., S. Mondal, R. Ravindran, et al. 2007. IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India. Journal of Immunology 179: 5592-5603.
17. Murray, H.W., A.L. Moreira, C.M. Lu, et al. 2003. Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis. Journal of Infectious Diseases 188: 458-464.
18. Nylen, S., R. Maurya, L. Eidsmo, et al. 2007. Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+ CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis. The Journal of Experimental Medicine 204: 805-817.
19. Nylen, S., and D. Sacks. 2007. Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends in Immunology 28: 378-384.
20. Karp, C.L., S.H. el-Safi, T.A. Wynn, et al. 1993. In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma. The Journal of Clinical Investigation 91: 1644-1648.
21. Caldas, A., C. Favali, D. Aquino, et al. 2005. Balance of IL-10 and interferon-gamma plasma levels in human visceral leishmaniasis: implications in the pathogenesis. BMC Infectious Diseases 5: 113.
22. Ansari, N.A., S. Saluja, and P. Salotra. 2006. Elevated levels of interferon-gamma, interleukin-10, and interleukin-6 during active disease in Indian kala azar. Clinical Immunology 119: 339-345.
23. de Medeiros, I.M., A. Castelo, and R. Salomao. 1998. Presence of circulating levels of interferon-gamma, interleukin-10 and tumor necrosis factor-alpha in patients with visceral leishmaniasis. Revista do Instituto de Medicina Tropical de São Paulo 40: 31-34.
24. Salhi, A., V. Rodrigues Jr., F. Santoro, et al. 2008. Immunological and genetic evidence for a crucial role of IL-10 in cutaneous lesions in humans infected with Leishmania braziliensis. Journal of Immunology 180: 6139-6148.
25. Karimabad, M.N., M.K. Arababadi, E. Hakimizadeh, et al. 2013. Is the IL-10 promoter polymorphism at position -592 associated with immune system-related diseases? Inflammation 36: 35-41.
26. Jiang, L., Z. Cheng, S. Qiu, et al. 2012. Altered let-7 expression in Myasthenia gravis and let-7c mediated regulation of IL-10 by directly targeting IL-10 in Jurkat cells. International Immunopharmacology 14: 217-223.
27. Farouk, S., M.A. Salih, A.M. Musa, et al. 2010. Interleukin 10 gene polymorphisms and development of post kala-azar dermal leishmaniasis in a selected Sudanese population. Public Health Genomics 13: 362-367.
28. Wang, C., X. Zhang, B. Zhu, et al. 2012. Relationships between tumour necrosis factor-alpha, interleukin-12B and interleukin-10 gene polymorphisms and hepatitis B in Chinese Han haemodialysis patients. Nephrology (Carlton, Vic.) 17: 167-174.
29. Ribeiro, C.S., J.E. Visentainer, and R.A. Moliterno. 2007. Association of cytokine genetic polymorphism with hepatitis B infection evolution in adult patients. Memórias do Instituto Oswaldo Cruz 102: 435-440.
30. Afzal, M.S., S. Tahir, A. Salman, et al. 2011. Analysis of interleukin-10 gene polymorphisms and hepatitis C susceptibility in Pakistan. Journal of Infection in Developing Countries 5: 473-479.
31. Swiatek, B.J. 2012. Is interleukin-10 gene polymorphism a predictive marker in HCV infection? Cytokine & Growth Factor Reviews 23: 47-59.